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Abstract
Background: Metabolic syndrome (MetS) is composed of cardiovascular risk factors including insulin resistance, 
obesity, dyslipidemia, and hypertension. Most of the components of MetS have been linked to the development of 
neoplasm. The purpose of this study was to evaluate the relationship between individual components of MetS and 
colorectal adenoma.
Methods: The study subjects were recruited from a pool of 4872 individuals who underwent a health check-up 
examination during the period January 2006 to May 2008. Each participant fulfilled a structured questionnaire. MetS 
was defined based on the America Heart Association and National Heart Lung Blood Institute criteria. Subjects with 
history of colon cancer, colon polyps, colitis, or prior colonic surgery were excluded.
Results: A total of 4122 subjects were included for final analysis (2367 men and 1755 women; mean age, 49.6 ± 11.7 
years). Of them, MetS was diagnosed in 708 men (29.9%) and in 367 women (20.9%). Among the patients with MetS, 
34.6% had adenoma, 31.7% had hyperplastic polyps and 23.3% were polyp-free (p < 0.0001, Chi-square test). The 
adjusted OR for colorectal adenoma was significantly higher in the subjects with MetS (OR, 1.31, CI: 1.09-1.57). A 
stronger association between MetS and colorectal adenoma was found in men (OR:1.44, CI:1.16-1.80) than in women 
(OR:1.04, CI:0.74-1.46). The adjusted OR for adenoma increased as the number of MetS components increased (p for 
trend = 0.0001 ). When the individual components of MetS were analyzed separately, only central obesity (OR:1.36, 
CI:1.14-1.63), low HDL cholesterol levels (OR:1.30, CI:1.10-1.54) and high triglyceride levels (OR:1.26, CI:1.04-1.53) were 
independently associated with colorectal adenoma.
Conclusions: Of the components of MetS analyzed in this study, central obesity and dyslipidemia are independent risk 
factors for colorectal adenoma. With regard to the prevention of colorectal neoplasm, life-style modification such as 
weight reduction is worthwhile.
Background
Metabolic syndrome (MetS), a collection of cardiovascu-
lar risk factors including central obesity, high blood pres-
sure, hyperglycemia, impaired glucose tolerance,
hypertriglyceridemia, as well as low levels of high density
lipoprotein cholesterol, is associated with an increased
risk of cardiovascular disease and diabetes [1-3]. Interest-
ingly, most of the components of metabolic syndrome
have also been linked individually to the development of
cancer [4-6].
Colorectal cancer is the second leading cause of the
cancer incidence and the third leading causes of the can-
cer death in Taiwan [7]. Several studies have found that
obesity, dyslipidemia and hyperglycemia are risk factors
for colorectal cancer [8-11]. Furthermore, recent epide-
miological studies have reported a positive correlation
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between metabolic syndrome and the presence of col-
orectal adenoma [12-14]. In order to prevent colorectal
cancer, it is crucial to identify the risk factors that are
associated with the development of colorectal neoplasia.
The aim of this study was to elucidate the relationship
between the components of MetS and prevalence of col-
orectal adenoma in a Chinese population.
Methods
Subjects
All the individuals attending China Medical University
Hospital for their routine health survey, during the period
January 2006 to May 2008, were invited to participate in
this study. A total of 5162 subjects were invited. Colonos-
copy was one of the health survey package. Each partici-
pant was asked to complete a structured questionnaire
designed to collect basic demographic data, medical his-
tory and lifestyle characteristics. Smoking status and
alcohol consumption history were divided into 3 classes
as follows: never, former, and current. For women, history
about menopause (yes/no), age of menopause, bilateral
oophorectomy (yes/no), and hormone replacement his-
tory (yes/no), duration of hormone replacement, were
also obtained.
All who willing to complete the health survey, age
greater than 30 y/o, were included in the study. Partici-
pants with a history of colon cancer, colon polyps, colitis,
or prior colonic surgery were excluded from the study.
Subjects with family history of familial adenomatous
polyposis and patients on life-long anticoagulant therapy
with risk of biopsy, were also excluded from the study. Of
the 4872 patients that were included, 513 did not sign the
consent form, 117 did not complete all phases of the
examination or did not undergo a polyp biopsy, and 124
were excluded because of a history of colon disease.
Therefore, the final study population was 4122 individu-
als (2367 men and 1755 women; mean age, 49.6 ± 11.7
years).
Anthrometric index and laboratory tests
Trained staff measured height, waist and hip circumfer-
ence (measured to the nearest 0.1 cm) and weight (mea-
sured to the nearest 0.1 kg). Weight was measured with
light clothing. Waist circumference (WC) was taken at
the midway point between the inferior margin of the last
rib and the superior iliac crest in a horizontal plane. Body
mass index (BMI) was calculated as weight (kg) divided
by height squared (m2). The same staff measured blood
pressure in the right arm using an appropriately sized cuff
and a standard mercury sphygmomanometer in a sitting
position. Blood was drawn with minimal trauma from an
antecubital vein in the morning after a 12-hour overnight
fast and was sent for analysis within four hours of blood
collection. Hs-CRP levels were measured by measured by
nephelometry, a latex particle-enhanced immunoassay
(TBA-200FR, Tokyo, Japan). The interassay and intraas-
say CVs were < 2.0% and < 1.9%, respectively. Biochemi-
cal markers such as total cholesterol, low-density
lipoprotein cholesterol (LDL-C), high-density lipoprotein
cholesterol (HDL-C), triglyceride, fasting glucose, creati-
nine, and uric acid were analyzed by a biochemical
autoanalyzer (Beckman Coulter, Lx-20, USA) at the
Department of Clinical Laboratory Diagnostics, China
Medical University Hospital.
Metabolic syndrome
MetS was defined clinically, based on the presence of
three or more of the following America Heart Associa-
tion and National Heart Lung Blood Institute (AHA/
NHLBI) metabolic syndrome criteria [15]: (1) central
obesity (waist circumference >0.9 m in men, and ≥0.8 m
in women), (2) high triglyceride level (≥ 1.7 mmol/L or on
drug treatment for elevated triglycerides), (3) low HDL-C
level (< 0.9 mmol/L in men and < 1.1 mmol/L in women
or on drug treatment for reduced HDL-C), (4) high blood
pressure (systolic BP≥ 130 mmHg or diastolic BP≥ 85
mmHg or under anti-hypertensive drug treatment in
patients with a history of hypertension), (5) high fasting
plasma glucose concentration (≥ 5.6mmol/L or on drug
treatment for elevated glucose).
Screening Colonoscopy
Bowel preparation was done with polyethylene glycol
lavage (Klean Prep Powder®, Helsinn-Birex Pharmaceuti-
cals, Dublin, Ireland) using a standard protocol identical
to that used for diagnostic colonoscopy . The screening
colonoscopy was performed by a gastroenterologist. The
colonoscope was inserted up to ileocecal area under
intravenous general anesthesia with dormicum and alfen-
tanil. Colonoscopic findings were categorized as polyp-
free; hyperplastic polyp (no potential of cancer change);
low grade adenoma; and high grade adenoma. A neo-
plasm was classified as a high-grade adenoma based on
the following features: a diameter of >1 cm, the presence
of three or more lesions, a villous component, or high-
grade dysplasia [16]. All the specimen were classified fol-
lowing a pathological examination at the Department of
Pathology, China Medical University Hospital. It has been
qualified by American College of Pathologist.
Statistical analysis
The data are presented as mean ± standard deviation
(SD) unless indicated otherwise. Log transformation was
used for variables with significant deviation from normal
distribution, followed by assessment by the Kolmogorov-
Smirnov test before further analyses. Analysis of variance
(ANOVA) was used for comparison of continuous vari-
ables. ANOVA with Scheffe's post hoc comparisons wasLiu et al. BMC Gastroenterology 2010, 10:51
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used. Each pair of the two groups' post hoc comparison
was statistically significant at α = 0.0036. Chi-square
analysis was used to compare the differences in preva-
lence of colon neoplasia across MetS groups. Multinomi-
nal logistic regression analysis was used to estimate the
ORs of colon polyps by age, MetS status, smoking and
alcohol consumption status. These statistical analyses
were performed using the PC version of SAS statistical
software (SAS 9.1.3 Service Pack 2, SAS Institute Inc.,
Cary, NC, USA). A two-sided p-value of less than 0.05
was considered significant.
We certify that all applicable institutional and govern-
mental regulations concerning the ethical use of human
v o l u n t e e r s  w e r e  f o l l o w e d  d u r i n g  t h i s  r e s e a r c h .  E t h i c s
approval for patient recruitment and analyzing the data
was obtained from the Institutional Review Board of
China Medical University Hospital in Taiwan.
Results
The prevalence of colon polyp and the individual compo-
nents of MetS in both sexes are shown in Table 1. Overall,
28.7% of the subjects had a central pattern of obesity,
27.8% had high blood pressure, 58.0% had low HDL-C
levels, 23.3% had high triglyceride levels, and 27.6% had
elevated glucose levels. In the study population, 26.0% of
the subjects (708 men (29.9%) and 367 women (20.9%))
had three or more components of metabolic syndrome.
Of the 4122 patients who underwent a screening
colonoscopy, 3062 (74.3%) were polyp-free and 1060
(25.7%) had at least one polyp. Among these patients,
hyperplastic polyp was diagnosed in 341(8.3%), low-
grade adenoma was diagnosed in 580 (14.1%) and high-
grade adenoma was diagnosed in 139 (3.4%) subjects
(Table 2). As a whole, subjects without colon polyps were
younger, had lower BMI values, waist circumference,
blood glucose levels, triglyceride levels, blood pressure,
and had higher HDL-C levels than those with colon pol-
yps. The prevalence rates of metabolic syndrome and
smoking (current or former) were lower in polyp-free
subjects than in patients with colon polyps.
The prevalence rate of MetS was 34.6% among subjects
with adenoma, 31.7% among those with hyperplastic pol-
yps and 23.3% among poly-free individuals (p < 0.0001,
Chi-square test). The prevalence of both low-grade and
high-grade adenoma increased steadily with the cumula-
tive number of components of MetS (Figure 1). The
adjusted OR for colorectal adenoma was significantly
higher in the subjects with MetS (OR, 1.31; CI, 1.09-1.57).
The adjusted OR for adenoma increased as the number of
components of MetS increased (p for trend = 0.0001 ).
Table 1: Prevalence (%) of metabolic syndrome (MetS), its individual components and colon polyps by sex
Women (n = 1755) Men (n = 2367) Total (N = 4122)
MetS (AHA/NHLBI criteria) 20.9 29.9 26.0
Individual components
Large waist 27.8 29.3 28.7
High BP 22.7 31.5 27.8
Low HDL-C 58.1 57.8 58.0
High triglycerides 13.5 30.7 23.3
Elevated fasting glucose 22.5 31.4 27.6
Number of components present
0 26.5 18.3 21.8
1 34.3 25.4 29.2
2 18.3 26.4 22.9
3 11.6 19.0 15.8
47 . 6 8 . 9 8 . 4
51 . 7 1 . 9 1 . 8
Colonoscopic findings
Polyp-free 80.9 69.4 74.3
Hyperplastic polyp 5.9 10.0 8.2
Low grade adenoma 10.6 16.6 14.1
High grade adenoma 2.6 4.0 3.4
Abbreviations: AHA/NHLBI, America Heart Association and National Heart Lung Blood Institute; BP, blood pressure; HDL-C, high-density 
lipoprotein cholesterol.Liu et al. BMC Gastroenterology 2010, 10:51
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This trend was not observed for hyperplastic polyps
(Table 3). When the individual components of MetS were
analyzed separately, only central obesity, low HDL-C lev-
els and high triglyceride levels were significantly associ-
ated with risk for colorectal adenoma (OR:1.36, 1.30, 1.26
respectively, Table 3). The adjusted OR for hyperplastic
polyp in the subjects with metabolic syndrome was not
significant (OR, 1.26; CI, 0.98-1.61).
The association between MetS and colorectal adenoma
was higher in men (OR:1.44, CI:1.16-1.80) than in women
(OR:1.04, CI:0.74-1.46). No effects of postmenopausal
status or hormone replacement therapy on the colorectal
adenoma were found in women. As for the individual
component of MetS, dyslipidemia and large waist showed
significant association with colon adenoma in men, but
not in women. Women had different manifestation, that
is, high blood pressure and large waist showed significant
association with hyperplastic polyp, a non-precancerous
lesions (table 4).
Discussion
The prevalence of MetS is increasing due to the escala-
tion of obesity and sedentary lifestyle worldwide. The
present study confirmed that certain components of
MetS increase the likelihood of colorectal adenoma, a
premalignant lesion of colorectal cancer.
Previous studies have found that MetS increases the
risk of colorectal adenoma by 1.3 to 2 times [12-14,17]. In
present study, we addressed the relationship between col-
orectal adenoma and the various features of MetS. Kim
[14] found that only large waist circumference was asso-
ciated with the development of colon adenoma. Lee [17]
and Wang [12] found that BMI and high triglyceride lev-
els were related to the development of colon or rectosig-
moid adenoma. We found that large waist circumference
and atherogenic dyslipidemia (low HDL-C and high trig-
lyceride) were associated with the development of col-
orectal adenoma when individual components were
analyzed separately. It is the first time to find the relation-
Table 2: Demographic and clinical characteristics of the subjects according to colonoscopic findings
Normal (0) 
N = 3062
Hyperplastic 
polyp (1) N = 341
Low-grade 
neoplasm (2) N = 579
High-grade 
neoplasm (3) N = 140
ANOVA 
Scheffe's test b
Age (yrs) 48.2 ± 11.5 51.5 ± 10.8 53. 5 ± 11.1 58.2 ± 11.4 0-1,0-2,0-3,
1-3,2-3
Gender (male)*a 1641 (53.6) 237 (69.5) 392 (67.7) 95 (67.8)
Metabolic syndrome*a 714 (23.3) 108 (31.7) 201 (34.7) 48 (34.3)
BMI (Kg/m2) 23.7 ± 3.6 24.7 ± 3.3 24.6 ± 3.4 24.1 ± 3.5 0-1,0-2
WC (m) 0.80 ± 0.10 0.84 ± 0.91 0.84 ± 0.96 0.84 ± 0.99 0-1,0-2,0-3
SBP (mmHg) 117.6 ± 15.0 120.5 ± 14.7 121.8 ± 15.4 121.8 ± 15.6 0-1,0-2,0-3
DBP (mmHg) 74.3 ± 9.4 76.7 ± 9.9 76.7 ± 9.3 77.2 ± 8.8 0-1,0-2,0-3
Glucose (mmol/L) 5.33 ± 1.40 5.59 ± 1.69 5.45 ± 1.14 5.50 ± 1.28 0-1
Cholesterol (mmol/L) 5.14 ± 0.99 5.14 ± 1.09 5.22 ± 1.04 5.23 ± 0.95 NS
Triglyceride (mmol/L) 1.30 ± 1.00 1.44 ± 0.95 1.49 ± 1.06 1.43 ± 1.25 0-2
HDL-C (mmol/L) 1.16 ± 0.34 1.07 ± 0.32 1.07 ± 0.32 1.09 ± 0.33 0-1,0-2
Log CRP† 0.08 ± 3.45 0.09 ± 3.52 0.12 ± 3.39 0.12 ± 3.09 0-2,0-3
Smoking status *a
current 589(19.8) 107(32.5) 168(29.9) 39(28.1)
former 265(8.9) 57(17.3) 66(11.7) 21(15.1)
never 2121(71.3) 165(50.2) 328(58.4) 79(56.8)
Alcohol drinking *a
current 835(28.0) 127(38.5) 193(34.5) 49(36.6)
former 75(2.5) 16(4.8) 33(5.9) 9(6.7)
never 2067(69.5) 187(56.7) 333(59.6) 76(56.7)
*p < 0.001 by χ2 test; a: data are presented as n (%); b:Analysis of variance (ANOVA) with Scheffe's post hoc comparisons, each pair of digits 
represented that two groups' post hoc comparison was statistically significant at α = 0.0036
† : Statistics were tested using the log-transformed values.
Abbreviations: BMI, body mass index; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL-C, high-density 
lipoprotein cholesterol; CRP, C-reactive protein;Liu et al. BMC Gastroenterology 2010, 10:51
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ship of colorectal adenoma and low serum HDL-C level
in the literature.
The possible mechanisms by which colorectal neo-
plasms arise in subjects with MetS comprise inflamma-
tion, insulin resistance and oxidative stress [18]. Adipose
tissue is now r ec ognized as an endocrine or gan ra t her
than a simple fat storage site, and a wide range of inflam-
matory cytokines is released from adipose tissue, includ-
ing C-reactive protein, tumor necrosis factor- and
interleukin-6 [19,20]. Adipose tissue can produce and
release the inflammatory cytokines that are potentially
procarcinogenic. The association of colorectal adenoma
and the inflammatory cytokines has been postulated [21-
23]. In our study, high-sensitivity C-reactive protein level
was significantly higher in MetS subjects with adenoma
than in MetS subjects without polyps. This could partly
explain the possible mechanism of such phenomenon.
Two studies have indicated that patients with multiple
components of MetS are at increased risk for colorectal
cancer mortality compared with the individual compo-
nents alone. Cluster analysis indicates that the effects of
the individual components are additive [11,18]. We also
found that the risk for colorectal ademoma increased
with the number of components of MetS.
The association between the MetS and colorectal ade-
noma was stronger for men than for women. Previous
studies have reported the same phenomenon [13,17];
however, those did not take menopausal status of women
or the use of hormone replacement therapy into account.
It is possible that the protective effect of estrogen or pro-
gesterone may be masking the true effects of metabolic
syndrome on colorectal neoplasms. The Women's Health
Table 3: Crude and adjusted odds ratios for colon polyps associated with metabolic syndrome and its components (N = 
4122)
Hyperplastic polyp N = 341 Adenoma (low and high grade) N = 719
Crude
OR (CI)
Adjusted
OR (CI)*
Crude
OR (CI)
Adjusted
OR (CI)*
Metabolic Syndrome
N = 2944 1.62 (1.28-2.05) 1.26 (0.98-1.61) 1.87 (1.58-2.22) 1.31 (1.09-1.57)
Number of metabolic syndrome components
1 (N = 1168) 1.17 (0.81-1.69) 1.13 (0.78-1.63) 1.34 (1.02-1.74) 1.23 (0.95-1.61)
2 (N = 914) 1.97 (1.38-2.81) 1.83 (1.28-2.61) 1.86 (1.42-2.43) 1.48 (1.13-1.94)
3 (N = 702) 1.99 (1.36-2.92) 1.45 (0.97-2.16) 2.54 (1.93-3.35) 1.61 (1.21-2.14)
> = 4 (N = 476) 2.45 (1.63-3.67) 2.06 (1.35-3.14) 2.66 (1.97-3.59) 1.70 (1.24-2.34)
Metabolic syndrome components
Large waist (N = 1179) 1.36 (1.06-1.72) 1.22 (0.96-1.56) 1.64 (1.38-1.94) 1.36 (1.14-1.63)
High BP (N = 1376) 1.61 (1.28-2.02) 1.29 (1.00-1.65) 1.68 (1.42-1.98) 1.08 (0.90-1.30)
Low HDL-C (N = 2389) 1.49 (1.17-1.91) 1.44 (1.14-1.82) 1.33 (1.12-1.59) 1.30 (1.10-1.54)
High triglyceride (N = 1030) 1.40 (1.09-1.79) 1.25 (0.97-1.62) 1.47 (1.23-1.76) 1.26 (1.04-1.53)
High glucose (N = 1149) 1.57 (1.24-1.99) 1.23 (0.96-1.58) 1.58 (1.33-1.88) 1.09 (0.91-1.31)
C-reactive proteina 1.12 (1.01-1.25) 1.05 (0.94-1.17) 1.17 (1.08-1.26) 1.08 (1.00-1.17)
*adjusted for age, gender, smoking and alcohol consumption status
a not a component of metabolic syndrome, analyzed as continuous variable after log-transformation
Abbreviations: BP, blood pressure; HDL-C, high-density lipoprotein cholesterol.
Figure 1 Prevalence rate (%) of hyperplastic polyp, low-grade ad-
enoma and high-grade adenoma according to the number of 
components of metabolic syndrome. The prevalence of both low-
grade and high-grade adenoma increased steadily with the cumula-
tive number of components of metabolic syndrome.
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Initiative Estrogen Plus Progestin trial suggested that
hormone replacement therapy reduced invasive colorec-
tal cancer by 44% [24]. However, a follow-up study of
women using estrogen alone did not reveal a reduction in
colorectal cancer incidence [25]. Gunter et al postulated
two pathways that are related to colon cancer; one involv-
ing endogenous estradiol, and the other involving obesity
and hyperinsulinemia [26]. In this study, we were unable
to confirm whether estrogen or progesterone has a pro-
tective effect on the development of colorectal adenoma.
More research is needed to clarify the reason for the gen-
der difference in the prevalence of colorectal adenoma in
patients with metabolic syndrome.
In addition to smoking and alcohol consumption, con-
founding factors for colon neoplasm include physical
activity, and dietary variables, which were not analyzed in
our study. Larsen IK et al [27] reveal that smoking and
BMI were the most significant risk factors for neoplasia,
but adhering to recommendations on diet and physical
activity seems also to be important.
In our study, similar distribution of demographic char-
acteristic between participants and non-participants
were found, indicating the kind of selection error might
be random. In addition, as long as individuals with the
MetS and colon polyps have equal probability of having
physical check-up as those individuals with MetS but no
colon polyps, the detection error will be random. Thus,
the biased results in the effect may be toward the null, a
lesser threat to validity.
To evaluate the potential misclassification of polyps/
adenoma, we measured the concordance rate of the
pathologists. The Kendall's Tau-b statistic was 0.978,
which meant a very high inter-rater reliability. The possi-
bility of outcome misclassification was minimal. There
also exists the possibility of a measurement error. The
inter-assay and intra-assay CVs for cholesterol, triglycer-
ide, glucose and HDL-C were < 4% and < 3%, respectively.
Such a measurement error is independent of colon polyp,
i.e., due to random error, the results in the effect may be
toward the null, a lesser threat to validity.
Conclusions
The present study of Chinese men and women revealed
that increased likelihood of colorectal adenoma, a prema-
lignant lesion of colorectal cancer, was associated with
MetS. Of them, central obesity and dyslipidemia were
independently increased for the risk of colorectal ade-
noma. With regard to the prevention of colorectal cancer,
life-style modification such as weight reduction is worth-
while.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
CSL, HSH, CCL and CCL contributed equally to the design of the study and
direction of its implementation, including supervision of the field activities,
quality assurance and control. WYL and TL supervised the field activities. CIL,
CIJ and YCC carried out the literature review and prepared the Materials and
Methods and the Discussion sections of the text. CSL and TCL designed the
study's analytic strategy and conducted the data analysis. All authors read and
approved the final version of the manuscript.
Acknowledgements
This study was supported by grant from the China Medical University Hospital 
(DMR-96-084), Taiwan Department of Health Clinical Trial and Research Center 
of Excellence (DOH99-TD-B-111-004) and National Science Council (NSC96-
2628-B-039-011-MY3).
The authors express their special thanks to the staff and subjects who partici-
pated in this study.
We certify that all our affiliations with or financial involvement in, within the 
past 5 years and foreseeable future, any organization or entity with a financial 
interest in or financial conflict with the subject matter or materials discussed in 
the manuscript are completely disclosed.
Table 4: Adjusted* ORs for colon polyps associated with metabolic syndrome (MetS) and its component according to 
gender
Women Men
Hyperplastic polyp
N = 104
Adenoma (low or high 
grade) N = 232
Hyperplastic polyp
N = 237
Adenoma (low or high 
grade) N = 487
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